Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 5

Asimetrik dimetilarjinin, NO ve kollateral gelişim

Asymmetric dimethylarginine, NO and collateral growth

Pages
417–420
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to evaluate the interrelations between ADMA and collateral growth.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atherosclerosis is a chronic inflammatory disease, which selectively involves the arteries in the vascular system.
📊
Key Findings & Data:Increased plasma ADMA levels are related with poor coronary collateral development.
💡
Conclusion & Impact:The aim of this review is to evaluate the interrelations between ADMA and collateral growth.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atherosclerosis is a chronic inflammatory disease, which selectively involves the arteries in the vascular system. Atherosclerosis develops because of reactions occurring in vessel wall beginning with response to endothelial injury. Endothelial dysfunction is characterized with impairment and loss of monolayer cells covering the inside of the vessels, which is endothelium. Endothelial dysfunction is the first stage in atherosclerosis. Coronary angiogenesis and collateral growth are chronic adaptations to myocardial ischemia to restore coronary blood flow and salvage myocardium in the ischemic region. Nitric oxide (NO) which represents the status of endothelial health plays a major role in collateral vessel development. Asymmetric dimethylarginine (ADMA) which is endogenous inhibitor of NO synthesis may impair the effective coronary collateral vessel development. Increased plasma ADMA levels are related with poor coronary collateral development. ADMA may be responsible for the difference in coronary collateral vessel development among similar patients with coronary artery disease. Nitric oxide inhibitors have a determinative relation with endothelial cell functions which may be integral prerequisite in all steps of collateral development. The aim of this review is to evaluate the interrelations between ADMA and collateral growth.

Özet

Ateroskleroz vasküler sistemde seçici olarak arterleri tutan kronik bir hastalıktır. Ateroskleroz endotel hasarına yanıt olarak damar duvarında başlayan inflamatuvar reaksiyonlar sonucu gelişir. Endotel disfonksiyonu damar içini kaplayan tek katlı hücre tabakası olan endotelin bozulması ve kaybı ile karakterizedir. Endotel disfonksiyonu aterosklerozda ilk aşamadır. Koroner anjiyogenez ve kollateral gelişim iskemik alanda koroner kan akımını yeniden sağlamak ve miyokardiyumu kurtarmak için miyokardiyal iskemiye yönelik kronik adaptasyonlardır. Nitrik oksit (NO) endotelin sağlık durumunu yansıtır ve kollateral damar gelişiminde önemli bir rol oynar. Asimetrik dimetilarjinin (ADMA) NO sentezinin endojen inhibitörüdür ve etkin bir koroner kollateral damar gelişimini engelleyebilir. Plazma ADMA düzeylerinin artışı zayıf koroner kollateral gelişim ile ilişkilidir. Asimetrik dimetilarjinin koroner arter hastalığı olan benzer hastalar arasındaki koroner kollateral gelişimin farklı olmasından sorumlu olabilir. Nitrik oksit inhibitörleri endotel hücre fonksiyonları ile belirleyici bir ilişkiye sahiptir ve korunmuş endotel fonksiyonları kollateral gelişimin tüm aşamalarının vazgeçilmez bir ön şartı olabilir. Bu derlemenin amacı ADMA ve kollateral gelişim arasındaki karşılıklı ilişkiyi değerlendirmektir.

🔖

Cite This Article

KOCAMAN, S. A. (2022). Asimetrik dimetilarjinin, NO ve kollateral gelişim. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 5, 417–420. https://ajindex.com/articles/436950

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow up study in 403 patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 1545-50
  2. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, et al. Influence of coronary collateral vessels on myocardial infarct size in humans: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. The TIMI investigators. Circulation 1991; 83: 739-46
  3. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 1989; 117: 290-5
  4. Maseri A, Araujo L, Finocchiaro ML. Collateral development and function in man. In: Schaper W, Schaper J, editors. Collateral circulation: heart, brain, kidney, limbs. Boston MA; Kluwer Academic Publishers: 199. P. 381-402
  5. Tayebjee MH, Lip GY, MacFadyen RJ. Collateralization and the response to obstruction of epicardial coronary arteries. QJM 2004; 97: 259-72
  6. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12
  7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5
  8. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23
  9. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92
  10. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7
  11. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 2001; 358: 2127-8
  12. Şahinarslan A, Çengel A, Biberoğlu G, Hasanoğlu A, Türkoğlu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis 2006; 17: 605-9
  13. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethy